TLR4 and peripheral arterial disease: •Key Findings: Pharmaceutical inhibition of the Toll-like receptor 4 pathway might be of clinical significance in patients with peripheral arterial disease, where it could be used as an adjunctive treatment to improve outcomes of treatments at different stages of the disease.